Aptargroup, Inc. (ATR) Stock Price & Analysis
Aptargroup, Inc. (ATR) rose 3.54% to USD 115.9 as of June 10, 2026 at 02:07 UTC, according to Nexqual real-time market data.
ATR last closed at USD 111.94; the session ranged USD 112.67–116.15 on volume of 331,030 shares. Market capitalization is $7.40B, with a 52-week range of USD 103.23–164.28 (NYQ). Source: Nexqual, June 10, 2026 at 02:07 UTC.
Key Statistics (as of June 10, 2026 at 02:07 UTC)
| Price | USD 115.9 |
|---|---|
| Change | ▲ 3.54% (up) |
| Previous Close | USD 111.94 |
| Open | USD 113.28 |
| Day Range | USD 112.67 – 116.15 |
| 52-Week Range | USD 103.23 – 164.28 |
| Volume | 331,030 shares |
| Market Cap | $7.40B |
| Exchange | NYQ |
Technical Analysis (ATR)
Nexqual's technical model rates ATR "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 02:07 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 47.62 (neutral) |
| vs SMA50 | Below (USD 121.57) |
| MACD | -2.34 (negative) |
Analyst Ratings (ATR)
Wall Street analysts rate ATR "Buy" based on 7 analysts, with a mean price target of USD 160.43 (range USD 140–220), per Nexqual as of June 10, 2026 at 02:07 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 160.43 |
| High Target | USD 220 |
| Low Target | USD 140 |
| Buy / Hold / Sell | 5 / 2 / 0 |
Earnings (ATR)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 1.36 |
| Revenue Estimate | $1.01B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.19 vs est 1.15 ▲ beat |
| 2025-12-31 | USD 1.25 vs est 1.23 ▲ beat |
| 2025-09-30 | USD 1.62 vs est 1.57 ▲ beat |
| 2025-06-30 | USD 1.66 vs est 1.59 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:07 UTC.
Financials & Fundamentals (ATR)
| Total Revenue | $3.87B |
|---|---|
| Revenue Growth (YoY) | +10.80% |
| Gross Margin | +36.67% |
| Operating Margin | +11.06% |
| Profit Margin | +9.98% |
| ROE | +14.80% |
| Debt / Equity | 53.72 |
| Current Ratio | 1.66 |
| Total Cash | $229.48M |
| Total Debt | $1.44B |
| Free Cash Flow | $253.01M |
Source: Nexqual, June 10, 2026 at 02:07 UTC.
Financial Health Score (ATR)
Nexqual rates Aptargroup, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 02:07 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 37%, operating 11% |
| Balance Sheet | Solid — $229M cash vs $1.44B debt |
| Cash Flow | Solid — FCF $253M, 7% margin |
| Efficiency | Mixed — ROE 15%, ROA 6.6% |
Ownership (ATR)
| Insider Ownership | +0.88% |
|---|---|
| Institutional Ownership | +96.90% |
| Shares Outstanding | 63.82M |
| Float | 63.19M |
| Short % of Float | +3.22% |
Source: Nexqual, June 10, 2026 at 02:07 UTC.
Leadership (ATR)
Aptargroup, Inc. is led by Stephan B. Tanda (age 60), President, CEO & Executive Director, per Nexqual as of June 10, 2026 at 02:07 UTC.
| President, CEO & Executive Director | Stephan B. Tanda (age 60) |
|---|---|
| Executive VP & CFO | Vanessa Kanu (age 47) |
| President of Aptar Pharma | Gael Touya (age 55) |
| President of Aptar Beauty | Marc Prieur (age 59) |
| Executive VP of Strategic Group Development & President of Aptar Asia | Xiangwei Gong (age 55) |
Major Backers & Investors (ATR)
Notable institutional backers of Aptargroup, Inc. include State Farm Mutual Automobile Insurance Co, Morgan Stanley, Victory Capital Management Inc., according to Nexqual as of June 10, 2026 at 02:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| State Farm Mutual Automobile Insurance Co | 7.43% |
| Morgan Stanley | 5.29% |
| Victory Capital Management Inc. | 3.79% |
| Eaton Vance Growth Trust-Eaton Vance Atlanta Capital SMID-Cap Fund | 2.98% |
| Victory Portfolios-Victory Sycamore Established Value Fund | 2.71% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 18.56% |
| BlackRock | 12.94% |
| State Street | 5.4% |
| Geode Capital | 2.65% |
| Dimensional Fund Advisors | 2.36% |
Source: Nexqual, June 10, 2026 at 02:07 UTC.
From Aptargroup, Inc.'s Latest SEC 10-K Filing (filed 2026-02-06)
Key Strengths & Strategy (as disclosed to the SEC)
- Leveraging our proprietary polymer-based technologies, we enable enhanced mitigation of impurities and degradation, product stability, shelf life, and performance across medical device, drug delivery, and selected food protection applications.
- While we expect that these types of new products will come to market in the future, it is difficult to estimate when, as the rigors of pharmaceutical regulations affect the timing of product introductions by our pharmaceutical customers that use our proprietary drug delivery systems.
- We have developed a multi-dose dispensing device suitable for ophthalmic formulations.
- Although Europe represents the largest region for us in terms of sales, our beauty and pharmaceutical customers often export their finished products using our technology around the world for consumption.
Partnerships
- Historically, the environmental impact of these processes has been minimal, and we collaborate with local permitting authorities to ensure we operate responsibly.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SLGN | Silgan Holdings Inc. | USD 38.7 | ▲ 5.65% |
| DCI | Donaldson Company, Inc. | USD 86.16 | ▲ 3% |
| CSL | Carlisle Companies Incorporated | USD 347.68 | ▲ 0.49% |
| SON | Sonoco Products Company | USD 49.9 | ▲ 5.07% |
| BRC | Brady Corporation | USD 76.44 | ▼ 13.75% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:07 UTC. This page is informational and not investment advice.